ロード中...
Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a n...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3533683/ https://ncbi.nlm.nih.gov/pubmed/23293509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S30951 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|